A clinical model for quality of life assessment in cancer patients receiving chemotherapy

Annals of Oncology

Volumn 11, Issue 1, 2000, Pages 23-30

  Klee, M C ^a,d   King, M T ^b   Machin, D ^c   Hansen, H H ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c MINISTRY OF HEALTH   (Singapore)

^d Rigshospitalet   (Denmark)

Author keywords

Clinical trials; Methodology; Ovarian cancer; Quality of life; Study design

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0033967901     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008394107982     Document Type: Article

References (22)

1. Fayers PM, Hopwood P, Girling DJ el al. Quality of life assessment in clinical trials - guidelines and a checklist for protocol writers: The UK Medical Research Council Experience. Eur J Cancer 1997; 35: 20-8.
2. Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assesments in clinical trials. Qual Life Res 1996; 5: 496-502.
3. Osoba D. Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Cancer Treat Rev 1996; 22: 69-73.
4. Hopwood P, Stephens RJ, Machin D. Approaches to the analysis of quality of life data: Experiences gained from a Medical Research Council Lung Cancer Working Party Palliative Chemotherapy trial. Qual Life Res 1994; 3: 339-52.
5. Huisman SJ, Van Dam FSAM, Aaronson NK, Hanewald GJFP. On measuring complaints of cancer patients: Some remarks on the time span of the question. In Aaronson NK, Beckmann J (eds): The Quality of Life of Cancer Patients. New York: Raven Press 1987; 101-8.
6. Hürny C, Bernhard J, Coates A et al. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation. Ann Oncol 1994; 5: 65-74.
7. Pater J, Osoba D, Zee B et al. Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: An example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual Life Res 1998; 7: 273-8.
8. Osoba D, Zee B, Pater J el al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-64.
9. Allison PJ, Locker D, Feine JS. Quality of life: A dynamic construct. Soc Sci Med 1997; 45: 221-30.
10. Sprangers MAG. Response shift bias: A challenge to the assessment of quality of life in cancer clinical trials. Cancer Treat Rev 1996; 22 (Suppl A): 55-62.
11. Klee M, Groenvold M, Machin D. Quality of life of Danish women: Population-based norms for the EORTC QLQ-C30. Qual Life Res 1997; 6: 27-34.
12. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Qualily-of-Life Questionnaire: The QLQ-C30 (+3). J Clin Oncol 1998; 1188-96.
13. Aaronson NK, Ahmedzai S, Bullinger M et al. The EORTC core quality-of-life questionnaire: Interim results of an international field study. In Osoba D (ed): Effect of Cancer on Quality of Life. Boston: CRC Press 1991; 185-203.
14. Fayers PM, Aaronson NK, Bjordal K, Sullivan M, EORTC QLQ-C30 Scoring Manual. Brussels: EORTC 1995; 1-49.
15. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76
16. Groenvold M, Klee M, Sprangers MAG, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assesment of patient -observer agreement. J Clin Epidemiol 1997; 50: 441-50.
17. Osoba D, Zee B, Warr D. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Comittees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997; 5: 307-13.
18. Rusthoven JJ, Osoba D, Butts CA. The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 1998; 6: 389-95.
19. Gridelli C, The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell-lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
20. Ekstrom K, Hoffman K, Linne T. Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study. Oncol Rep 1998; 5: 931-4.
21. Hammerlid E, Mercke C, Sullivan M. A prospective quality of life study of patients with laryngeal carcinoma by tumor stage and different radiation therapy schedules. Laryngoscope 1998; 108: 747-59.
22. Simons JFHA, Aaronson NK, Vansteenkiste JF et al. Effects of Medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: A placebo-controlled multicenter study. J Clin Oncol 1996; 14: 1077-84.